IO Biotech price target raised to $14 from $12 at H.C. Wainwright
Sponsored
Description
IO Biotech price target raised to $14 from $12 at H.C. Wainwright
Source link
Similar
Wells Fargo Raises PT on Health Catalyst, Inc. (HCAT); Maintains ‘Buy’ Rating
Access to this page has been denied.
Jim Cramer Reveals How Its Merger Could Succeed
Why NIKE (NKE) Could Be a Comeback Story Among the Dogs of the Dow
Lantheus Holdings Expands Alzheimer’s Diagnostics Despite Recent Stock Dip